Strategic analysis of an emerging biopharmaceutical company

Company X is an emerging biopharmaceutical company focused on the development of innovative new apoptotic inhibitor medical therapeutics. The company's main goal is for drug candidate XYZ to become the leading protective therapeutic in cases of acute heart attacks/reperfusion injury; and, to become a leading biopharmaceutical specializing in apoptotic pathways. This paper provides a strategic analysis of Company X's current strategic intent in order to firstly, assess its strategic fit in terms of an industrial partnership within the anti-reperfusion injury market and secondly, identify the competencies and key issues associated in implementing its current main goal. The result of this analysis has shown that though a strategic fit does exist, there are a number of key issues that Company X must overcome and key competencies it must acquire for a successful partnership.